Pharmacological characterization of repeated administration of the first generation abused synthetic cannabinoid CP47,497

Journal of Basic and Clinical Physiology and Pharmacology

Volumn 27, Issue 3, 2016, Pages 217-228

  Grim, Travis W ^a   Samano, Kimberly L ^a   Ignatowska Jankowska, Bogna ^a   Tao, Qing ^a   Sim Selly, Laura J ^a   Selley, Dana E ^a   Wise, Laura E ^a   Poklis, Alphonse ^a   Lichtman, Aron H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

CB1 receptor; dependence; designer drugs; synthetic cannabinoid; tolerance

Indexed keywords

CANNABINOID; CANNABINOID 1 RECEPTOR; CP47 497; DRONABINOL; RIMONABANT; UNCLASSIFIED DRUG; CANNABINOID RECEPTOR ANTAGONIST; ENDOCANNABINOID; GUANINE NUCLEOTIDE BINDING PROTEIN; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CROSS TOLERANCE; DRUG DETERMINATION; DRUG DISCRIMINATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERANCE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; REPEATED DRUG DOSE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM;

ANIMALS; CANNABINOID RECEPTOR ANTAGONISTS; CANNABINOIDS; DRONABINOL; DRUG TOLERANCE; ENDOCANNABINOIDS; FEMALE; GTP-BINDING PROTEINS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1;

EID: 84969776953     PISSN: 07926855     EISSN: 21910286     Source Type: Journal    
DOI: 10.1515/jbcpp-2015-0118     Document Type: Article

References (60)

1. Schultes RE. Hallucinogens of plant origin. Science 1969;163:245-54.
2. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990;87:1932-6.
3. Devane WA, Dysarz FAI, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605-13.
4. EMCDDA. European Monitoring Centre for Drugs and Drug Addiction. Thematic paper - Understanding the "Spice" phenomenon. Available at: http://www. emcdda. europa. eu/publications/ thematic-papers/spice. 2009. p. 1-34.
5. Lindigkeit R, Boehme A, Eiserloh I, Luebbecke M, Wiggermann M, Ernst L, et al. Spice: a never ending story? Forensic Sci Int 2009;191:58-63.
6. Ogata J, Uchiyama N, Kikura-Hanajiri R, Goda Y. DNA sequence analyses of blended herbal products including synthetic cannabinoids as designer drugs. Forensic Sci Int 2013;227:33-41.
7. Uchiyama N, Kikura-Hanajiri R, Kawahara N, Haishima Y, Goda Y. Identification of a cannabinoid analog as a new type of designer drug in a herbal product. Chem Pharm Bull (Tokyo) 2009;57: 439-41.
8. The Drug Enforcement Administration. CP-47, 497 seized in Wisconsin. Microgram Bull 2009;42:89-102.
9. Compton DR, Johnson MR, Melvin LS, Martin BR. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther 1992;260:201-9.
10. Compton DR, Rice KC, De Costa BR, Razdan RK, Melvin LS, Johnson MR, et al. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 1993;265:218-26.
11. Melvin LS, Johnson MR, Harbert CA, Milne GM, Weissman A. A cannabinoid derived prototypical analgesic. J Med Chem 1984;27:67-71.
12. Melvin LS, Milne GM, Johnson MR, Subramaniam B, Wilken GH, Howlett AC. Structure-activity relagionships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol Pharmacol 1993;44:1006-15.
13. Weissman A, Milne GM, Melvin LS. Cannabimimetic activity from CP-47, 497, a derivative of 3-phenylcyclohexanol. J Pharmacol Exp Ther 1982;223:516-23.
14. Logan BK, Reinhold LE, Xu A, Diamond FX. Identification of synthetic cannabinoids in herbal incense blends in the United States. J Forensic Sci 2012;57:1168-80.
15. Hudson S, Ramsey J. The emergence and analysis of synthetic cannabinoids. Drug Test Anal 2011;3:466-78.
16. Hudson S, Ramsey J, King L, Timbers S, Maynard S, Dargan PI, et al. Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in "herbal high" products. J Anal Toxicol 2010;34:252-60.
17. Auwärter V, Dresen S, Weinmann W, Müller M, Pütz M, Ferreirós N. "Spice" and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 2009;44: 832-7.
18. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 2007;10:870-9.
19. Martin WJ, Patrick SL, Coffin P, Tsou K, Walker JM. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sci 1995;56:2103-9.
20. Varvel SA, Wiley JL, Yang R, Bridgen DT, Long K, Lichtman AH, et al. Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology (Berl) 2006;186:226-34.
21. Wiley JL, Smith FL, Razdan RK, Dewey WL. Task specificity of cross-tolerance between Delta9-tetrahydrocannabinol and anandamide analogs in mice. Eur J Pharmacol 2005;510:59-68.
22. Lichtman AH, Poklis JL, Poklis A, Wilson DM, Martin BR. The pharmacological activity of inhalation exposure to marijuana smoke in mice. Drug Alcohol Depend 2001;63:107-16.
23. Huffman JW, Dai D, Martin BR, Compton DR. Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg Med Chem Lett 1994;4:563-6.
24. Little J, Compton DR, Johnson MR, Melvin LS, Martin BR. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther 1988;247:1046-51.
25. Wiley JL, Compton DR, Dai D, Lainton JA, Phillips M, Huffman JW, et al. Structure-activity relationships of indole- and pyrrole- derived cannabinoids. J Pharmacol Exp Ther 1998;285: 995-1004.
26. Compton DR, Gold LH, Ward SJ, Balster RL, Martin BR. Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct for delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 1992;263:1118-26.
27. Sim-Selley LJ, Schechter NS, Rorrer WK, Dalton GD, Hernandez J, Martin BR, et al. Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration. Mol Pharmacol 2006;70:986-96.
28. Hutcheson DM, Tzavara ET, Smadja C, Valjent E, Roques BP, Hanoune J, et al. Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9- tetrahydrocannabinol. Br J Pharmacol 1998;125:1567-77.
29. Macfarlane V, Christie G. Synthetic cannabinoid withdrawal: a new demand on detoxification services. Drug Alcohol Rev 2015;34:147-53.
30. Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, et al. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 1991;40:471-8.
31. Järbe TU, Henriksson BG. Discriminative response control produced with hashish, tetrahydrocannabinols (delta 8-THC and delta 9-THC), and other drugs. Psychopharmacologia 1974;40: 1-16.
32. Justinova Z, Tanda G, Redhi GH, Goldberg SR. Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology (Berl) 2003;169:135-40.
33. Wiley JL, Matthew Walentiny D, Vann RE, Baskfield CY. Dissimilar cannabinoid substitution patterns in mice trained to discriminate (9)-tetrahydrocannabinol or methanandamide from vehicle. Behav Pharmacol 2011;22:480-8.
34. Rinaldi-Carmona M. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994;350: 240-4.
35. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 1999;96:5780-5.
36. Selley DE, Stark S, Sim LJ, Childers SR. Cannabinoid receptor stimulation of guanosine-5-O-(3-[35S]thio)triphosphate binding in rat brain membranes. Life Sci 1996;59:659-68.
37. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
38. Wiley J. Cannabinoid pharmacological properties common to other centrally acting drugs. Eur J Pharmacol 2003;471:185-93.
39. Gamage TF, Ignatowska-Jankowska BM, Wiley JL, Abdelrahman M, Trembleau L, Greig IR, et al. In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569. Behav Pharmacol 2014;25:182-5.
40. Falenski KW, Thorpe AJ, Schlosburg JE, Cravatt BF, Abdullah RA, Smith TH, et al. FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration. Neuropsychopharmacology 2010;35:1775-87.
41. Colquhoun D. Lectures on biostatistics: an introduction to statistics with applications in biology and medicine. Oxford, UK: Clarendon Press, 1971:327-32.
42. Burkey TH, Quock RM, Consroe P, Roeske WR, Yamamura HI. delta 9-Tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain. Eur J Pharmacol 1997;323:R3-4.
43. Griffin G, Atkinson PJ, Showalter VM, Martin BR, Abood ME. Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes. J Pharmacol Exp Ther 1998;285:553-60.
44. Melvin LS, Johnson MR. Structure-activity relationships of tricyclic and nonclassical bicyclic cannabinoids. NIDA Res Monogr 1987;79:31-47.
45. Atwood BK, Lee D, Straiker A, Widlanski TS, Mackie K. CP47, 497-C8 and JWH073, commonly found in "Spice" herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists. Eur J Pharmacol 2011;659:139-45.
46. Martin BR. Structural requirements for cannabinoid-induced antinociceptive activity in mice. Life Sci 1985;36:1523-30.
47. Compton DR, Aceto MD, Lowe J, Martin BR. In vivo characterization of a specific cannabinoid receptor antagonist (SR141617A): inhibition of delta-9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 1996;277:586-94.
48. Monory K, Blaudzun H, Massa F, Kaiser N, Lemberger T, Schütz G, et al. Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice. PLoS Biol 2007;5:e269.
49. Alozie SO, Martin BR, Harris LS, Dewey WL. 3H-delta 9- Tetrahydrocannabinol, 3H-cannabinol and 3H-cannabidiol: penetration and regional distribution in rat brain. Pharmacol Biochem Behav 1980;12:217-21.
50. Samano KL, Poklis JL, Lichtman AH, Poklis A. Development of a high-performance liquid chromatography-tandem mass spectrometry method for the identification and quantification of CP-47, 497, CP-47, 497-C8 and JWH-250 in mouse brain. J Anal Toxicol 2014;38:307-14.
51. Wiley JL, Marusich JA, Lefever TW, Antonazzo KR, Wallgren MT, Cortes RA, et al. AB-CHMINACA, AB-PINACA, and FUBIMINA: affinity and potency of novel synthetic cannabinoids in producing 9-tetrahydrocannabinol-like effects in mice. J Pharmacol Exp Ther 2015;354:328-39.
52. McMahon LR, Ginsburg BC, Lamb RJ. Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice. Psychopharmacology (Berl) 2008;198:487-95.
53. Wiley JL, Lefever TW, Cortes RA, Marusich JA. Cross-substitution of 9-tetrahydrocannabinol and JWH-018 in drug discrimination in rats. Pharmacol Biochem Behav 2014;124:123-8.
54. Gatch MB, Forster MJ. 9-Tetrahydrocannabinol-like discriminative stimulus effects of compounds commonly found in K2/Spice. Behav Pharmacol 2014;25:750-7.
55. Martin BR, Sim-Selley LJ, Selley DE. Signaling pathways involved in the development of cannabinoid tolerance. Trends Pharmacol Sci 2004;25:325-30.
56. Rubino T, Patrini G, Parenti M, Massi P, Parolaro D. Chronic treatment with a synthetic cannabinoid CP-55, 940 alters G-protein expression in the rat central nervous system. Brain Res Mol Brain Res 1997;44:191-7.
57. Rubino T, Viganò D, Massi P, Parolaro D. Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55, 940. J Neurochem 2000;75:2080-6.
58. Allsop DJ, Copeland J, Norberg MM, Fu S, Molnar A, Lewis J, et al. Quantifying the clinical significance of cannabis withdrawal. PLoS One 2012;7:e44864.
59. Tai S, Nikas SP, Shukla VG, Vemuri K, Makriyannis A, Järbe TUC. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist. Psychopharmacology (Berl) 2015;232:2751-61.
60. Wise LE, Varvel SA, Selley DE, Wiebelhaus JM, Long KA, Middleton LS, et al. delta(9)-Tetrahydrocannabinoldependent mice undergoing withdrawal display impaired spatial memory. Psychopharmacology (Berl) 2011;217: 485-94.